Beyond the Guidelines in the Treatment of Peripheral T-Cell Lymphoma: New Drug Development

Peripheral T-cell lymphomas (PTCLs) are a rare and diverse group of neoplasms with a poor prognosis. Management of these disorders has been largely extrapolated from the treatment of aggressive B-cell lymphomas; however, therapeutic responses to this approach are neither adequate nor durable for most patients with PTCL. Given the rarity of PTCL, much of the literature consists of studies with small sample size and anecdotal case reports. Therefore, no consensus exists on the best therapeutic strategy for either newly diagnosed or relapsed/refractory PTCL. This article reviews promising novel approaches in the treatment of PTCL and its subtypes. Investigation into the pathogenesis of PTCL has also identified new targets for treatment. These emerging therapies include new uses of existing agents and the development of novel agents specifically targeted against T-cell lymphoma. Results using antimetabolites, immunotherapies, and histone deacetylase inhibitors have been particularly encouraging. These novel therapies are being tested as single agents and in combination with conventional lymphoma regimens in the frontline and salvage settings. Because of the rarity and heterogeneity of PTCL, national and international cooperation is needed to conduct the clinical studies required for the development of more effective treatment paradigms. These efforts are ongoing and will hopefully guide new strategies to improve the historically poor outcome of PTCL.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Ranjana H. Advani, MD, Stanford University Medical Center, Division of Oncology, 875 Blake Wilbur Drive, Stanford, CA 94305. E-mail: radvani@stanford.edu

Disclosure: Kerrin G. Robinson, MA, has disclosed no relevant financial relationships.

References

  • 1.

    JaffeESHarrisNLSteinHVardimanJW. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.

    • Search Google Scholar
    • Export Citation
  • 2.

    SavageKJChhanabhaiMGascoyneRDConnorsJM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol2004;15:14671475.

    • Search Google Scholar
    • Export Citation
  • 3.

    VoseJM. International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: poor outcome by prognostic indices and lack of efficacy with anthracyclines [abstract]. Blood2005;106: Abstract 811.

    • Search Google Scholar
    • Export Citation
  • 4.

    GisselbrechtCGaulardPLepageE. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood1998;92:7682.

    • Search Google Scholar
    • Export Citation
  • 5.

    Lopez-GuillermoACidJSalarA. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol1998;9:849855.

    • Search Google Scholar
    • Export Citation
  • 6.

    GallaminiAStelitanoCCalviR. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood2004;103:24742479.

    • Search Google Scholar
    • Export Citation
  • 7.

    WentPAgostinelliCGallaminiA. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol2006;24:24722479.

    • Search Google Scholar
    • Export Citation
  • 8.

    EscalonMPLiuNSYangY. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer2005;103:20912098.

    • Search Google Scholar
    • Export Citation
  • 9.

    GressinRPeochMDeconinckE. The VIP-ABVD regimen is not superior to the CHOP 21 for the treatment of non epidermotropic peripheral T cell lymphoma. Final results of the ``LTP95'' protocol of the GOELAMS [abstract]. Blood2006;108:Abstract 2464.

    • Search Google Scholar
    • Export Citation
  • 10.

    RodriguezJCondeEGutierrezA. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol2007;79:338.

    • Search Google Scholar
    • Export Citation
  • 11.

    CorradiniPTarellaCZallioF. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia2006;20:15331538.

    • Search Google Scholar
    • Export Citation
  • 12.

    KewalramaniTZelenetzADTeruya-FeldsteinJ. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol2006;134:202207.

    • Search Google Scholar
    • Export Citation
  • 13.

    ChenAIMcMillanANegrinRS. Long term results of autologous hematopoietic cell transplantation (AHCT) for peripheral T cell lymphoma: the Stanford experience [abstract]. Blood2007;110: Abstract 1906.

    • Search Google Scholar
    • Export Citation
  • 14.

    CorradiniPDoderoAZallioF. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol2004;22:21722176.

    • Search Google Scholar
    • Export Citation
  • 15.

    FeylerSPrinceHMPearceR. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant2007;40:443450.

    • Search Google Scholar
    • Export Citation
  • 16.

    ZelenetzADAdvaniRHBociekRG. The NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas version 32007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf. Accessed December 24 2007.

    • Search Google Scholar
    • Export Citation
  • 17.

    DangNHProBHagemeisterFB. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol2007;136:439447.

    • Search Google Scholar
    • Export Citation
  • 18.

    FossFSjak-ShieNGoyA. Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-cell lymphomas (PTCL), the CONCEPT trial [abstract]. Blood2007;110: Abstract 3449.

    • Search Google Scholar
    • Export Citation
  • 19.

    LundinJHagbergHReppR. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood2003;101:42674272.

    • Search Google Scholar
    • Export Citation
  • 20.

    DeardenCEMatutesECazinB. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood2001;98:17211726.

  • 21.

    EnbladGHagbergHErlansonM. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood2004;103:29202924.

    • Search Google Scholar
    • Export Citation
  • 22.

    ZinzaniPLAlinariLTaniM. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica2005;90:702703.

    • Search Google Scholar
    • Export Citation
  • 23.

    GallaminiAZajaFPattiC. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood2007;110:23162323.

    • Search Google Scholar
    • Export Citation
  • 24.

    KimJGSohnSKChaeYS. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol2007;60:129134.

    • Search Google Scholar
    • Export Citation
  • 25.

    WeidmannEHessGKrauseSW. A phase II immunochemotherapy study with alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas [abstract]. Blood2006;108:Abstract 2721.

    • Search Google Scholar
    • Export Citation
  • 26.

    KimYHDuvicMObitzE. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood2007;109:46554662.

    • Search Google Scholar
    • Export Citation
  • 27.

    d'AmoreFRadfordJJerkemanM. Zanolimumab (HuMax-CD4TM), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma [abstract]. Blood2007;110:Abstract 3409.

    • Search Google Scholar
    • Export Citation
  • 28.

    CasaleDABartlettNLHurdDD. A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma/leukemia [abstract]. Blood2006;108:Abstract 2727.

    • Search Google Scholar
    • Export Citation
  • 29.

    UikeNTsukasakiKUtsunomiyaA. Phase I study of KW-0761, a humanized anti-CCR4 antibody, in patients (pts) with relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) and peripheral T-cell lymphoma (PTCL): preliminary results [abstract]. Blood2007;110:Abstract 4492.

    • Search Google Scholar
    • Export Citation
  • 30.

    SallahSWanJYNguyenNP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol2001;113:185187.

  • 31.

    ZinzaniPLMagagnoliMBendandiM. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol1998;9:13511353.

  • 32.

    TsimberidouAMGilesFDuvicM. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M. D. Anderson Cancer Center series. Cancer2004;100:342349.

    • Search Google Scholar
    • Export Citation
  • 33.

    CzuczmanMSPorcuPJohnsonJ. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma2007;48:97103.

    • Search Google Scholar
    • Export Citation
  • 34.

    DuvicMForero-TorresAFossF. Response to oral forodesine in refractory cutaneous T-cell lymphoma: interim results of a phase I/II study [abstract]. Blood2007;110:Abstract 122.

    • Search Google Scholar
    • Export Citation
  • 35.

    O'ConnorOAHamlinPAGerecitanoJ. Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-cell lymphomas: results of the MSKCC phase I/II experience [abstract]. Blood2006;108:Abstract 400.

    • Search Google Scholar
    • Export Citation
  • 36.

    DuvicMTalpurRNiX. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood2007;109:3139.

    • Search Google Scholar
    • Export Citation
  • 37.

    OlsenEAKimYHKuzelTM. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol2007;25:31093115.

    • Search Google Scholar
    • Export Citation
  • 38.

    KimYHReddySKimEJ. Romidepsin (depsipeptide) induces clinically significant responses in treatment-refractory CTCL: an international, multicenter study [abstract]. Blood2007;110:Abstract 123.

    • Search Google Scholar
    • Export Citation
  • 39.

    PiekarzRLFryeRTurnerM. Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228 [abstract]. J Clin Oncol2005;23: Abstract 3061.

    • Search Google Scholar
    • Export Citation
  • 40.

    AdvaniRHymesKPohlmanB. Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma: results of a phase II study [abstract]. Blood2007;110: Abstract 3453.

    • Search Google Scholar
    • Export Citation
  • 41.

    ZinzaniPLMusuracaGTaniM. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol2007;25:42934297.

    • Search Google Scholar
    • Export Citation
  • 42.

    FeldmanALSunDXLawME. Syk tyrosine kinase is overexpressed in the majority of peripheral T- and NK-cell lymphomas, and represents a potential therapeutic target [abstract]. Blood2007;110:Abstract 690.

    • Search Google Scholar
    • Export Citation
  • 43.

    StreubelBVinatzerUWillheimM. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia2006;20:313318.

    • Search Google Scholar
    • Export Citation
  • 44.

    WiernikPHLossosISTuscanoJ. Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin lymphoma [abstract]. J Clin Oncol2007;25:Abtract 8052.

    • Search Google Scholar
    • Export Citation
  • 45.

    QuerfeldCKuzelTMGuitartJRosenST. Preliminary results of a phase II study of CC-5013 (Lenalidomide, Revlimid) in patients with cutaneous T-cell lymphoma [abstract]. Blood2005;106:Abstract 3351.

    • Search Google Scholar
    • Export Citation
  • 46.

    de LevalLRickmanDSThielenC. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood2007;109:49524963.

    • Search Google Scholar
    • Export Citation
  • 47.

    DupuisJBoyeKMartinN. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol2006;30:490494.

    • Search Google Scholar
    • Export Citation
  • 48.

    GroggKLAttygalleADMaconWR. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol2006;19:11011107.

    • Search Google Scholar
    • Export Citation
  • 49.

    TanBTWarnkeRAArberDA. The frequency of B- and T-cell gene rearrangements and Epstein-Barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn2006;8:466475.

    • Search Google Scholar
    • Export Citation
  • 50.

    ZhaoWLMourahSMounierN. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest2004;84:15121519.

    • Search Google Scholar
    • Export Citation
  • 51.

    DunleavyKWilsonWHJaffeES. Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Curr Opin Hematol2007;14:348353.

    • Search Google Scholar
    • Export Citation
  • 52.

    AdvaniRHorwitzSZelenetzAHorningSJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma2007;48:521525.

    • Search Google Scholar
    • Export Citation
  • 53.

    JolyBFrenkelVGaulardP. Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma (AITL). Preliminary results in 9 patients treated in a single institution [abstract]. Blood2005;106:Abstract 2686.

    • Search Google Scholar
    • Export Citation
  • 54.

    JorgensenJMSorensenFBBendixK. Expression pattern and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR and Flt-4 in peripheral T-cell lymphomas [abstract]. Blood2007;110:Abstract 689.

    • Search Google Scholar
    • Export Citation
  • 55.

    BrunsIFoxFReineckeP. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia2005;19:19931995.

    • Search Google Scholar
    • Export Citation
  • 56.

    NagafujiKFujisakiTArimaFOhshimaK. L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol2001;74:447450.

    • Search Google Scholar
    • Export Citation
  • 57.

    YongWZhengWZhuJ. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol2006;24:2832.

    • Search Google Scholar
    • Export Citation
  • 58.

    Forero-TorresABernsteinSHGopalA. SGN-30 (Anti-CD30 mAb) has a single-agent response rate of 21% in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL) [abstract]. Blood2006;108:Abstract 2718.

    • Search Google Scholar
    • Export Citation
  • 59.

    AnsellSMHorwitzSMEngertA. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol2007;25:27642769.

    • Search Google Scholar
    • Export Citation

Article Information

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 30 30 8
PDF Downloads 7 7 3
EPUB Downloads 0 0 0